Chemical: Drug
rosiglitazone

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for rosiglitazone

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C8 *3 N/A N/A N/A
No VIP available CA VA
rs10192566 NC_000002.11:g.11890428C>G, NC_000002.12:g.11750302C>G, NG_012843.2:g.77724C>G, NM_001261427.1:c.9+8874C>G, NM_001261428.1:c.139-15231C>G, NM_001261429.1:c.9+8874C>G, NM_145693.2:c.-10+3631C>G, XM_006711869.1:c.139-15231C>G, XM_006711870.2:c.9+8874C>G, XM_006711871.1:c.-10+3631C>G, XM_006711872.1:c.-9-15231C>G, XM_011510333.1:c.139-15231C>G, XM_011510334.1:c.9+8874C>G, XM_011510335.1:c.-128+4101C>G, XM_011510336.1:c.-10+4101C>G, XM_011510337.1:c.139-15231C>G, XM_011510338.1:c.139-15231C>G, rs58869681
C > G
SNP
No VIP available No Clinical Annotations available VA
rs10229583 NC_000007.13:g.127246903G>A, NC_000007.14:g.127606849G>A, rs17659573, rs61359821
G > A
SNP
No VIP available CA VA
rs10509681 NC_000010.10:g.96798749T>C, NC_000010.11:g.95038992T>C, NG_007972.1:g.35506A>G, NM_000770.3:c.1196A>G, NM_001198853.1:c.986A>G, NM_001198854.1:c.890A>G, NM_001198855.1:c.986A>G, NP_000761.3:p.Lys399Arg, NP_001185782.1:p.Lys329Arg, NP_001185783.1:p.Lys297Arg, NP_001185784.1:p.Lys329Arg, XR_246073.1:n.1331A>G, XR_945610.1:n.1331A>G, rs17522568, rs56435423, rs61450273
T > C
SNP
K399R
No VIP available No Clinical Annotations available VA
rs11572080 NC_000010.10:g.96827030C>T, NC_000010.11:g.95067273C>T, NG_007972.1:g.7225G>A, NM_000770.3:c.416G>A, NM_001198853.1:c.206G>A, NM_001198854.1:c.110G>A, NM_001198855.1:c.206G>A, NP_000761.3:p.Arg139Lys, NP_001185782.1:p.Arg69Lys, NP_001185783.1:p.Arg37Lys, NP_001185784.1:p.Arg69Lys, XR_246073.1:n.512G>A, XR_945610.1:n.512G>A, rs60090616
C > T
SNP
R139K
No VIP available No Clinical Annotations available VA
rs1801282 NC_000003.11:g.12393125C>G, NC_000003.12:g.12351626C>G, NG_011749.1:g.68777C>G, NM_005037.5:c.-2-28078C>G, NM_015869.4:c.34C>G, NM_138711.3:c.-2-28078C>G, NM_138712.3:c.-2-28078C>G, NP_056953.2:p.Pro12Ala, XM_011533840.1:c.-2-28078C>G, XM_011533841.1:c.-2-28078C>G, XM_011533842.1:c.34C>G, XM_011533843.1:c.34C>G, XM_011533844.1:c.-2-28078C>G, XP_011532144.1:p.Pro12Ala, XP_011532145.1:p.Pro12Ala, rs17241090, rs17749580, rs36206375, rs56460253, rs57327233
C > G
SNP
P12A
No VIP available No Clinical Annotations available VA
rs2970847 NC_000004.11:g.23815924T>C, NC_000004.12:g.23814301T>C, NG_028250.1:g.80777A>G, NM_013261.3:c.1182A>G, NP_037393.1:p.Thr394=, XM_005248130.1:c.1197A>G, XM_005248130.2:c.1197A>G, XM_005248131.1:c.1194A>G, XM_005248131.3:c.1194A>G, XM_005248132.1:c.1173A>G, XM_005248133.1:c.1146A>G, XM_005248134.1:c.1197A>G, XM_005248134.3:c.1197A>G, XM_011513764.1:c.1182A>G, XM_011513765.1:c.1146A>G, XM_011513766.1:c.1077A>G, XM_011513767.1:c.1077A>G, XM_011513768.1:c.1077A>G, XM_011513769.1:c.1197A>G, XM_011513770.1:c.801A>G, XM_011513771.1:c.801A>G, XP_005248187.1:p.Thr399=, XP_005248188.1:p.Thr398=, XP_005248189.1:p.Thr391=, XP_005248190.1:p.Thr382=, XP_005248191.1:p.Thr399=, XP_011512066.1:p.Thr394=, XP_011512067.1:p.Thr382=, XP_011512068.1:p.Thr359=, XP_011512069.1:p.Thr359=, XP_011512070.1:p.Thr359=, XP_011512071.1:p.Thr399=, XP_011512072.1:p.Thr267=, XP_011512073.1:p.Thr267=, rs17847357, rs60288662
T > C
SNP
T394T
No VIP available CA VA
rs6467136 NC_000007.13:g.127164958A>G, NC_000007.14:g.127524904A>G, XR_927939.1:n.387+10245T>C, rs10340096, rs386602922, rs57595087
A > G
SNP
No VIP available No Clinical Annotations available VA
rs8192678 NC_000004.11:g.23815662C>T, NC_000004.12:g.23814039C>T, NG_028250.1:g.81039G>A, NM_013261.3:c.1444G>A, NP_037393.1:p.Gly482Ser, XM_005248130.1:c.1459G>A, XM_005248130.2:c.1459G>A, XM_005248131.1:c.1456G>A, XM_005248131.3:c.1456G>A, XM_005248132.1:c.1435G>A, XM_005248133.1:c.1408G>A, XM_005248134.1:c.1459G>A, XM_005248134.3:c.1459G>A, XM_011513764.1:c.1444G>A, XM_011513765.1:c.1408G>A, XM_011513766.1:c.1339G>A, XM_011513767.1:c.1339G>A, XM_011513768.1:c.1339G>A, XM_011513769.1:c.1459G>A, XM_011513770.1:c.1063G>A, XM_011513771.1:c.1063G>A, XP_005248187.1:p.Gly487Ser, XP_005248188.1:p.Gly486Ser, XP_005248189.1:p.Gly479Ser, XP_005248190.1:p.Gly470Ser, XP_005248191.1:p.Gly487Ser, XP_011512066.1:p.Gly482Ser, XP_011512067.1:p.Gly470Ser, XP_011512068.1:p.Gly447Ser, XP_011512069.1:p.Gly447Ser, XP_011512070.1:p.Gly447Ser, XP_011512071.1:p.Gly487Ser, XP_011512072.1:p.Gly355Ser, XP_011512073.1:p.Gly355Ser, rs17847358, rs52829424, rs56570248, rs56707915
C > T
SNP
G482S
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Rosigliazone maleate
  • Rosiglitazone maleate
  • rosiglitazone
Trade Names
  • Avandia
  • Rosiglizole
Brand Mixture Names
  • Avandamet (Metformin hydrochloride + Rosiglitazone maleate)
  • Avandaryl (Glimepiride + Rosiglitazone maleate)

PharmGKB Accession Id

PA451283

Type(s):

Drug

Description

Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).

Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARgamma. Rosiglitazone is a selective ligand of PPARgamma, and has no PPARalpha-binding action.

Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NF¿B) levels fall and inhibitor (I¿B) levels increase in patients on rosiglitazone.

Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.

Source: Drug Bank

Indication

For the treatment of Type II diabetes mellitus

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Rosiglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.

Source: Drug Bank

Pharmacology

Rosiglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Rosiglitazone targets insulin resistance and, hence, is used alone or with metformine or sulfonylurea to improve glycemic control in patients with type 2 diabetes mellitus.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. Rosiglitazone is extensively metabolized in the liver to inactive metabolites via N-demethylation, hydroxylation, and conjugation with sulfate and glucuronic acid. In vitro data have shown that Cytochrome (CYP) P450 isoenzyme 2C8 (CYP2C8) and to a minor extent CYP2C9 are involved in the hepatic metabolism of rosiglitazone.

Source: Drug Bank

Protein Binding

99.8% bound to plasma proteins, primarily albumin.

Source: Drug Bank

Absorption

The absolute bioavailability of rosiglitazone is 99%. Peak plasma concentrations are observed about 1 hour after dosing. Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in C max and a delay in T max (1.75 hours). These changes are not likely to be clinically significant; therefore, rosiglitazone may be administered with or without food.

Source: Drug Bank

Half-Life

3-4 hours

Source: Drug Bank

Toxicity

Side effects include fluid retention, congestive heart failure (CHF), liver disease

Source: Drug Bank

Clearance

Source: Drug Bank

Route of Elimination

Following oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively.

Source: Drug Bank

Volume of Distribution

  • 6 L

Source: Drug Bank

Chemical Properties

Chemical Formula

C18H19N3O3S

Source: Drug Bank

Isomeric SMILES

CN(CCOC1=CC=C(C=C1)C[C@@H]2C(=O)NC(=O)S2)C3=CC=CC=N3

Source: Drug Bank

CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=NC=CC=C1

Source: Drug Bank

Canonical SMILES

CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1

Source: Drug Bank

Average Molecular Weight

357.427

Source: Drug Bank

Monoisotopic Molecular Weight

357.114712179

Source: Drug Bank

SMILES

CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1

Source: Drug Bank

InChI String

InChI=1/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Rosiglitazone Pathway, Pharmacokinetics
    Rosiglitazone is transported from hepatic sinusoids into hepatocytes -- a process mediated by the organic anion transporting polypeptide, where is is metabolized by cytochrome p450 2C8 and 2C9.

External Pathways

Links to non-PharmGKB pathways.

  1. visceral fat deposits and the metabolic syndrome - (BioCarta via Pathway Interaction Database)

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ACSL4 (source: Drug Bank)
PPARG (source: Drug Bank)

Drug Interactions

Interaction Description
gemfibrozil - rosiglitazone Increases the effect and toxicity of rosiglitazone/pioglitazone (source: Drug Bank)
gemfibrozil - rosiglitazone Increases the effect and toxicity of rosiglitazone/pioglitazone (source: Drug Bank)
ketoconazole - rosiglitazone Ketoconazole increases the effect of rosiglitazone (source: Drug Bank)
ketoconazole - rosiglitazone Ketoconazole increases the effect of rosiglitazone (source: Drug Bank)
pregabalin - rosiglitazone Increased risk of edema (source: Drug Bank)
pregabalin - rosiglitazone Increased risk of edema (source: Drug Bank)
rifampin - rosiglitazone Rifampin reduces levels and efficacy of rosiglitazone (source: Drug Bank)
rifampin - rosiglitazone Rifampin reduces levels and efficacy of rosiglitazone (source: Drug Bank)
rosiglitazone - somatropin recombinant Somatropin may antagonize the hypoglycemic effect of rosiglitazone. Monitor for changes in fasting and postprandial blood sugars. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to rosiglitazone: 32

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients. The pharmacogenomics journal. 2014. Chen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenetics and genomics. 2013. Aquilante Christina L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARgamma on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenetics and genomics. 2013. Stage Tore B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro investigation of the glutathione S-transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals. 2011. Usui Toru, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of KCNQ1 Polymorphisms on the Therapeutic Efficacy of Oral Antidiabetic Drugs in Chinese Patients With Type 2 Diabetes. Clinical pharmacology and therapeutics. 2011. Yu W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. American journal of obstetrics and gynecology. 2010. Hemauer Sarah J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clinical pharmacology and therapeutics. 2009. Wagner J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009. Daily Elizabeth B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A highly annotated whole-genome sequence of a Korean individual. Nature. 2009. Kim Jong-Il, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. Arteriosclerosis, thrombosis, and vascular biology. 2009. Lee Choon-Soo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Human genomics. 2008. Aquilante Christina L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics. 2008. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients. Acta pharmacologica Sinica. 2008. Wang Jie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. British journal of clinical pharmacology. 2008. Kalliokoski Annikka, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
LPIN1 genetic variation is associated with rosiglitazone response in type 2 diabetic patients. Molecular genetics and metabolism. 2008. Kang Eun Seok, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar. Pharmacogenetics and genomics. 2007. Spraggs Colin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
[The effect of single nucleotide polymorphism SNP + 45 of the adiponectin gene on the rosiglitazone maleate response in patients with type 2 diabetes]. Zhonghua yi xue za zhi. 2007. Zhang Hua, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients. Clinical pharmacology and therapeutics. 2007. Haider D G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). The pharmacogenomics journal. 2007. Roses A D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. British journal of clinical pharmacology. 2006. Pedersen Rasmus S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clinical pharmacology and therapeutics. 2006. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Molecular diagnosis & therapy. 2007. Bozkurt Ozlem, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rosiglitazone treatment enhances acute AMP-activated protein kinase-mediated muscle and adipose tissue glucose uptake in high-fat-fed rats. Diabetes. 2006. Ye Ji-Ming, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. Diabetes care. 2006. Kang Eun Seok, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS medicine. 2006. Yang Rong-Ze, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Molecular cancer therapeutics. 2006. Han ShouWei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clinical pharmacology and therapeutics. 2005. Kang Eun Seok, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2005. Lee Kyung S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evidence for a potent antiinflammatory effect of rosiglitazone. The Journal of clinical endocrinology and metabolism. 2004. Mohanty Priya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug metabolism and disposition: the biological fate of chemicals. 2004. Nozawa Takashi, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0029-3158-18
DrugBank:
DB00412
PDB:
BRL
ChEBI:
50122
KEGG Drug:
D00596
PubChem Compound:
77999
PubChem Substance:
46504556
7980539
IUPHAR Ligand:
1056
Drugs Product Database (DPD):
2241113
BindingDB:
28681
ChemSpider:
70383
HET:
BRL
Therapeutic Targets Database:
DAP000271
FDA Drug Label at DailyMed:
ab8bf594-5238-407b-a1ae-5ddd087603ef

Clinical Trials

These are trials that mention rosiglitazone and are related to either pharmacogenetics or pharmacogenomics.

No trials found.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.